Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care
The Institute for Clinical and Economic Review, a drug pricing watchdog, gave a measured thumbs up on Thursday morning to bluebird’s potentially expensive new gene therapy for a rare but debilitating blood disorder, which will go before an FDA advisory committee next Friday.
While bluebird raised some sticker-shock eyebrows with its proposed price of $2.1 million per treatment course of what’s known as beti-cel, ICER said previously in April and again today that the therapy would be cost-effective, as long as there’s an 80% payback option for patients who do not achieve and maintain transfusion independence over a five-year period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
